Clonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards ...

FDA Drug Recall #D-0135-2017 — Class III — September 28, 2016

Recall Summary

Recall Number D-0135-2017
Classification Class III — Low risk
Date Initiated September 28, 2016
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Location Rockford, IL
Product Type Drugs
Quantity 1,182 unit dose cards of 300 (10 punch cards of 30 tablets each) and 52,618 unit dose blister cards (10 cards of 10 tablets each)

Product Description

Clonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards (NDC 51079-881-20) and b) 300-count unit dose box of 10 x 30 punch cards (NDC 51079-881-56), Rx only, Manufactured by Mylan Pharmaceuticals Inc, Morgantown, WV, 26505

Reason for Recall

Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.

Distribution Pattern

Nationwide

Lot / Code Information

Lot#: a) 3061779, Exp 11/16; 3071447, Exp 04/17; b)3071789, Exp 04/17

Other Recalls from Mylan Institutional, Inc. (d.b.a. UDL...

Recall # Classification Product Date
D-0861-2022 Class II Esomeprazole Magnesium Delayed-Release Capsules... Apr 1, 2022
D-0860-2022 Class II Esomeprazole Magnesium Delayed-Release Capsules... Apr 1, 2022
D-1013-2019 Class II Alprazolam Tablets, USP, 0.25 mg, 10x10 per car... Jan 18, 2019
D-1112-2018 Class III Diltiazem HCl Extended-release Capsules, USP 12... Aug 14, 2018
D-0822-2018 Class II Loxapine Capsules, USP 25 mg, packaged in 100 U... May 1, 2018

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.